CHF Solutions Initiatives at HFSA 24th Annual Scientific Meeting Highlight Aquadex Therapy Performance in Heart Failure
Key highlights on Aquadex™ Therapy at VirtualHFSA2020 include:
- Clinical Study Data from “Ten Year Experience of Ultrafiltration for Management of Acute Decompensated Heart Failure (ADHF)” presented during the Live Poster Chats on
Saturday, October 3 andSunday, October 4 from1:15 to 2:45pm ET . - Case Study on “Outpatient Ultrafiltration to prevent Hospital Readmission During COVID-19 Pandemic in Diuretic Intolerant Patient: Case Study” presented during the Live Poster Chats on
Saturday, October 3 andSunday, October 4 from1:15 to 2:45pm ET . - Virtual booth at https://virtual.hfsa.org/node/301597/exhibithall/0/422944#lct=exhibithall-422944 with an opportunity to ask questions of CHF Solutions’ clinical specialists and access educational materials regarding the treatment of heart failure patients, including the recent webinar “Precision Medicine for the Treatment of Fluid Overload in Patients with Acute Heart Failure” presented by Dr.
John Jefferies , the Jay M. Sullivan Distinguished Chair in Cardiovascular Medicine and Chief of Cardiology at theUniversity of Tennessee Health Science Center .
“This year’s virtual platform provides medical professionals with efficient access to valuable information and clinical data. We are excited to share how the Aquadex system has proven to be advantageous in the delivery of effective care for heart failure patients and patients with COVID-19,” said
About
About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements about the company’s initiatives in connection with the 24th Annual Scientific Meeting of the
CONTACTS INVESTORS:Claudia Napal Drayton Chief Financial Officer,CHF Solutions, Inc. 952-345-4205 ir@chf-solutions.com MEDIA:Jessica Stebing Health+Commerce 260-336-6202 jstebing@healthandcommerce.com
Source: CHF Solutions, Inc.